News
Entertainment
Science & Technology
Life
Culture & Art
Hobbies
News
Entertainment
Science & Technology
Culture & Art
Hobbies
Boehringer Ingelheim Drug Wins FDA Approval for Treating Fatal Lung Disorder IPF - MedCity News
Boehringer Ingelheim’s Jascayd blocks a protein involved in the lung inflammation that develops from idiopathic pulmonary fibrosis, a rare and ultimately fatal disease with few available therapies. The twice-daily pill doesn’t cure IPF but clinical trial results showed it slowed disease progression.
White House AI Action Plan: What Healthcare Leaders Must Do Now - MedCity News
Healthcare and life sciences are about to face unprecedented AI-driven regulatory changes that will reshape everything from research and development to drug approval submissions. Here are 10 steps healthcare and life sciences organizations should take to strategically prepare.
The Tariff Opportunity for Medtech: Building the Supply Chain of the Future - MedCity News
The current tariff volatility creates a new set of challenges for medtech companies, but uncertainty is here to stay. Companies must act now, building on the trade compliance capabilities they are building to create a resilient supply chain that is ready for future disruptions.
Inside a Big Q3: Venture Capital for Digital Health Continues to Grow - MedCity News
Digital health funding remains strong so far this year, with $9.9 billion raised through Q3 and megarounds driving record deal sizes. However, the path to scale is becoming less predictable, as startups increasingly rely on unlabeled rounds and face longer timelines to reach Series B.
Skye Bio Obesity Drug Fails in Phase 2; Hopes Now Ride on Higher Doses and Combo Treatment - MedCity News
While Skye Bioscience said its drug nimacimab may yet achieve better weight loss results with higher doses, the company and analysts are interested in the drug’s potential to be combined with Novo Nordisk’s Wegovy. Skye’s drug is an antibody designed to preferentially target CB1 receptors in the gut, offering an alternative approach to activating GLP-1 receptors.
FDA Pilot Program Creates New Path for Faster Regulatory Review of Generic Drugs - MedCity News
The FDA will provide faster regulatory review of generic drugs that are tested in and manufactured in the U.S. using domestically sourced active pharmaceutical ingredients. This FDA pilot program is part of a broader Trump administration strategy to reshore pharmaceutical production.
Meeting Patients Where They Are: The Value of Innovation & Collaboration in Expanding Kidney Care Access - MedCity News
This requires leveraging technology and partnerships in new ways to break down traditional barriers, designing therapies to fit more seamlessly into patients’ lives, and creating more equitable access to life-sustaining treatments.
If the Record Doesn’t Reflect the Risk, the Rating Won’t Reflect the Care - MedCity News
Documentation gaps can quietly undermine everything from how your organization is publicly rated, to how they are reimbursed, to how payers evaluate your performance, leading to weaker negotiating power, and decreased ability to recruit top talent or attract patients.
Over-the-Counter CGMs Are Here — But Do They Really Make Sense for Non-Diabetics? - MedCity News
Over-the-counter continuous glucose monitors have been available for people with and without diabetes for more than a year now — but the data they collect doesn’t seem to be as useful for nondiabetic users, according to new research from Mass General Brigham.
Rocket Pharmaceuticals Pulls FDA Filing for Rare Blood Disorder Gene Therapy - MedCity News
Rocket Pharmaceuticals voluntarily withdrew the FDA submission for its Fanconi anemia gene therapy. The move follows a corporate restructuring over the summer that refocused the company on its cardiovascular programs.
Cartography Bio Corrals $67M to Bring Targeted Colorectal Cancer Drug Into the Clinic - MedCity News
Pfizer Ventures led the Series B financing of Cartography Biosciences, whose lead program addresses a promising target for colorectal cancer. The startup’s drugs come from platform technologies that analyze data from healthy cells and cancer cells to identify cancer-specific targets.
Scaling Radioligand Therapy: 3 Essential Strategies From Inside The Ecosystem - MedCity News
Success requires orchestrating an end-to-end experience that connects manufacturing, logistics, clinical sites, payers, and patients seamlessly. The companies that treat this orchestration as a strategic competency, rather than just operational logistics, will be best positioned to scale.
Debunked Episode 20: A Look at H-1B Visas in Healthcare, M&A Deals for Bitcoin and More - MedCity News
MedCity News Editor in Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch, also discussed whether bitcoin would play a greater role in healthcare deals and the Trump administration's mixed messages on autism and Tylenol.
Hackensack Meridian Health Launches Trial of Canine-Powered Cancer Detection - MedCity News
Hackensack Meridian Health launched a clinical trial with Israeli startup SpotitEarly, which is developing a cancer test that combines AI with trained dogs to analyze patients’ breath. The study aims to validate this noninvasive approach alongside traditional screenings, potentially enabling earlier and more accessible cancer detection.
Thinking with Our Gut: How the Management of GI Conditions is Evolving - MedCity News
Through new diagnostic methods, integrated approaches and innovative management solutions, patients no longer have to live with discomfort. Here are three major ways the GI field is evolving to better care for patients today.
The Burgeoning Life Science Ecosystem of North Texas, Anchored by Pegasus Park - MedCity News
At INVEST Digital Health 2025, David Snow, Executive Director of Pegasus Park, discussed building a life science innovation hub and why life science startups at the North Texas campus are more likely to survive, scale, and exit.
Novartis Nabs FDA Approval for First-of-Its-Kind Drug for Chronic Hives - MedCity News
Novartis drug Rhapsido is now approved as a second-line treatment for chronic spontaneous urticaria, a rare inflammatory skin disease. Additional clinical trials are ongoing to support potential expansion of the twice-daily pill to other immunological disorders.
Pfizer Reaches Deal on Most-Favored Nation Drug Pricing; Other Pharmas Expected to Follow - MedCity News
Newly launched Pfizer drugs will be priced at parity to prices in comparable developed nations, according to the most-favored nation pricing agreement. But industry observers note that big pharma companies are also raising some prices overseas as part of a strategy to protect U.S. revenue.
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs - MedCity News
September has seen a wide range of executive hires, exits, promotions and layoffs across the healthcare industry. For example, Medtronic, Amgen and Kaiser Permanente welcomed new executives. There were also layoffs at organizations including Novo Nordisk and Seattle Children’s.
Why Healthcare Mergers Fail and How to Prevent a Costly Collapse - MedCity News
Successful mergers don’t just consolidate services. They unify people around a shared mission to serve their patients. If we want to see lasting success in healthcare M&A, it’s time to stop leading with checklists and start leading with people.
Startup Crystalys Therapeutics Emerges With $205M to Fill a Growing Gap in Gout Treatment - MedCity News
Crystalys Therapeutics’ gout drug, dotinurad, inhibits a known and validated target for treating the chronic disorder, but in a way that could be safer than other drugs. The oral small molecule was discovered and developed in Japan, where it is approved and has a safety record spanning more than 1 million gout patients.